BioSpace News Archive

Business

Sanofi and Jennifer Doudna-Founded Scribe Ink $1B CRISPR Cell Therapy Deal

Sanofi has inked a licensing deal with Scribe Therapeutics to develop novel natural killer (NK) cell therapies for cancer using Scribe’s CRISPR genome editing technology.

September 27, 2022
·
2 min read
·
Mark Terry
Drug Development

FDA Hits Avidity’s AOC for Myotonic Dystrophy Type 1 with Partial Hold

The FDA ordered Avidity Biosciences to halt clinical trial enrollment after a patient suffered a “serious adverse event” testing the company’s candidate drug for myotonic dystrophy type 1.

September 27, 2022
·
2 min read
·
Paul Elias
Drug Development

Vertex, CRISPR to Submit Exa-Cel to FDA for Sickle Cell and Beta Thalassemia

The FDA has granted a rolling review to CRISPR Therapeutics and Vertex’s exa-cel, a potential one-time treatment for sickle cell disease and transfusion-dependent beta-thalassemia.

September 27, 2022
·
2 min read
·
Rosemary Scott
Drug Development

Transgene Promises Value Adding Clinical Milestones on R&D Day

During an R&D presentation Tuesday, Transgene executives and oncology experts highlighted promising therapeutic progress in its programs - focusing on its developmental cancer vaccines.

September 27, 2022
·
3 min read
·
Alex Keown
Business

“De-Extinction” Company Colossal Launches Form Bio to Maximize Tech

Colossal started the “de-extinction” of the thylacine, commonly known as the Tasmania tiger. Now with a $30 million investment, this technology is gaining more traction.

September 27, 2022
·
2 min read
·
Paul Elias
Business

5 Life Science Companies Drive Innovation in Lone Star Bio

FUJIFILM Dyosynth Biotechnologies, Taysha Gene Therapies, Veravas highlight innovation stemming from the Lone Star state. BioSpace takes a deep dive into these and other Texas innovators.

September 27, 2022
·
6 min read
·
Alex Keown
Business

Exicure Lays off Two-Thirds of Workforce, Suspends R&D in Restructuring

Shares of Exicure, Inc. are falling after the company announced a strategic initiative that casts doubts on its future developmental programs.

September 27, 2022
·
2 min read
·
Alex Keown
Policy

Eli Lilly Becomes Latest Biopharma Sued for Alleged Age Discrimination

The U.S. Equal Employment Opportunity Commission filed a lawsuit Monday against Eli Lilly and Co. alleging the company refused to hire older workers for sales representative positions.

September 27, 2022
·
2 min read
·
Mark Terry
R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data

Transgene, a biotech company that designs and develops virus-based immunotherapeutics against cancer, will host an R&D event for investors and research analysts in Paris.

September 27, 2022
·
5 min read
Pharm Country

Teleflex launches new Arrow® Pressure Injectable Midline Catheter Portfolio

Teleflex Incorporated releases their new Arrow® Pressure Injectable Midline portfolio in the US and Canada, designed to help alleviate line identification confusion.

September 27, 2022
·
4 min read